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Low raltegravir transfer into the breastmilk of a woman living with HIV
A raltegravir-based regimen is among the preferred for
pregnant women living with HIV [1,2], making
raltegravir a widely used antiretroviral drug in new
mothers in high-income countries. European [1] and US
[2] guidelines recommend against breastfeeding because
of the potential risk of mother-to-child transmission
(MTCT). Nevertheless, an increasing number of HIV-
infected mothers is breastfeeding their newborns [3], and
it is an ongoing debate if the cultural, psychological and
social importance of breastfeeding outweighs the MTCT
risk in some circumstances [4–8]. Adequate antiretroviral
therapy is of particular importance in these women to
prevent transmission, but it is widely unknown, which
antiretroviral drugs (ARVs) are preferable for these
women [5]. Here, we present the first case of raltegravir
in a breastfeeding mother.
A 36-year-old HIV-1-infected woman received raltegravir
800 mg once daily (decreased dose because of low body
weight) and emtricitabine/tenofovir disoproxil 200/245 mg
once daily. Her plasma HIV-RNA has remained<20 cop-
copies/ml for more than 6 years. At 41þ 3 weeks of
gestation, she delivered a healthy boy (3580 g, 55 cm,
APGAR score 9 at 5 min), who received neonatal
prophylaxis with oral zidovudine for 14 days [9].
Breastfeeding was chosen, with exclusive breastfeeding
until 4 months of age followed by mixed feeding until the
age of 9 months. A mild elevation of total bilirubin levels
with normal liver function tests was observed at 14, 32, 48,
and 90 days of age (6.71 [conjugated 0.61], 4.58, 5.99, and
1.42 mg/dl, respectively). Infant HIV-DNA PCR results
were consistently negative up to the age of 8 months.
Maternal blood (at 4 months) and breastmilk samples (4
and 8 months postpartum) were obtained for pharmaco-
kinetic analyses after observed maternal raltegravir intake
with food to assess the breastmilk transfer and estimate
infant exposure to raltegravir. A single infant blood
sample was taken at 4 h after maternal dosing (assumed
Tmax) to assess the infant’s exposure. The plasma samples
were analyzed using a validated ultra-performance liquid
chromatography tandem mass spectrometry assay [lower
limit of quantification (LLOQ) 0.01 mg/l] [10]. The
method was adapted for analysis of breastmilk samples,
which were determined relative to a breastmilk linear
calibration curve (0.01–10 mg/l) resulting in circa results
of the breastmilk concentration.
An AUC0–12h milk-to-plasma (M:P) ratio of 0.46 was
calculated from the paired data of 4 months postpartum
(noncompartmental analysis using Phoenix 63), indicating
low raltegravir transfer into the breastmilk and little
accumulation. A similar M:P ratio (range 0.37–0.71) was
observed during the sampling interval (Fig. 1a). A similar
breastmilk exposure and M : P ratio (0.55) was observed at
8 months postpartum (Fig. 1b). The unexpected delayed
Tmax (12 h) at 4 months postpartum could be attributed to a
migraine attack the woman suffered from during blood
collection and/or the erratic absorption of raltegravir
[11,12].
At 4 and 8 months postpartum, the infant’s raltegravir
plasma concentrations (45 min after last breastfeeding)
were below the LLOQ (Fig. 1). At 4 months postpartum,
the estimated infant dosage of the exclusively breastfed
infant was 0.099 mg/kg/day, based on an average infant
daily milk intake of 150 ml/kg, weight of 6.7 kg, and an
average raltegravir breastmilk concentration of 0.66 mg/l
(derived from AUC0–12h) [13]. This estimated daily
infant dosage corresponded to 0.8% of the approved daily
raltegravir dose of 12 mg/kg/day [14].
We showed for the first time that raltegravir can
penetrate into breastmilk. The clinical relevance of
infant exposure to different ARVs via breastmilk is
discussed critically. Therapeutic antiretroviral infant
exposure may protect against HIV transmission,
whereas low level antiretroviral exposure can result
in the development of resistance and false-negative
HIV-tests in case of infection [15,16]. The relative
raltegravir dose ingested by the tested infant is unlikely
to be of therapeutic clinical significance as it seems to
be less than 1% of the approved treatment dose and the
infant exposure is beneath the protein-adjusted IC95 of
0.016 mg/l [17].
Raltegravir and bilirubin are both metabolized by
UGT1A1 and compete for albumin binding sites [18].
In this case, the UGT1A1 activity of the infant was
probably matured at the time of sampling, whereas low
UGT1A1 activity in neonates may result in higher
raltegravir concentrations [18,19]. The observed hyper-
bilirubinemia could, therefore, be not only attributed to
the raltegravir exposure via breastmilk but also to
intrauterine raltegravir exposure as reported in non-
breastfed infants after intrauterine integrase inhibitor
exposure [20–22]. More longitudinal data, especially in
the neonatal period, are needed to establish the
applicability of raltegravir in breastfeeding HIV-infected
mothers.
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(Charite-Universitätsmedizin Berlin), the mother gave
written informed consent.
Acknowledgements
The authors wish to thank the patient and her family for
participating in the study.
The PANNA network is supported by the European
AIDS Treatment Network/European Commission/DG
Research, Sixth Framework program (contract LSHP-
CT-2006-037570), Gilead B.V., Bristol Myers Squibb,
ViiV Healthcare, Merck Sharp & Dohme Corp, and
Janssen Pharmaceutica.
Conflicts of interest
There are no conflicts of interest.
Cornelia Feiterna-Sperlinga, Vera E. Bukkemsb,
Marga J.A. Teulenb, Angela P. Colbersb, on behalf of
the PANNA networkaDepartment of Pediatric Pneu-
monology, Immunology and Intensive Care Medicine,
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Is a step-down antiretroviral therapy necessary to fight severe acute respiratory syndrome coronavirus 2 in
HIV-infected patients?
At present, no evidence exists that people living with HIV
(PLWHIV) are at increased risk of contracting severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
compared with the general population or experiencing a
worse outcome.
There is also no evidence that PLWHIV receiving a
protease inhibitor-based regimen have a lower incidence
of coronavirus disease 2019 (COVID-19) compared with
PLWHIV receiving other regimens.
At the time of writing, COVID-19 management and
outcome have been described in nine PLWHIV, all
treated with protease inhibitors [1–3]. The first case has
been described in Asia and was a naı̈ve patient who
received lopinavir/ritonavir (LPV/r)-containing first-line
therapy [1]. A few days later, Blanco et al. [2] reported a
case series of five HIV and SARS-CoV-2 coinfected
patients in Spain, of whom four were already on
antiretroviral therapy (ART) and one was an ART naive
AIDS presenter. Also in this case, they were all treated
with protease inhibitors: one patient maintained a
darunavir/ritonavir (DRV/r)-based treatment; two
replaced dolutegravir with LPV/r; one replaced DRV/
r with LPV/r; while the naı̈ve patient started a first-line
ARTwith cobicistat boosted DRV (DRV/c). Finally, also
Riva et al. described a case series of PLWHIV in Italy,
who were all already treated with DRV/c, and in which
the protease inhibitor treatment failed to prevent
COVID-19, despite adequate DRV plasma levels. In
two of them, the authors replaced DRV/c with LPV/r
[3]. All these reported cases were discharged alive from
hospital [1–3], but their follow-up is too short to evaluate
the efficacy of their new antiretroviral strategies.
The use of LPV/r is not supported by evidence in the
current COVID-19 epidemic but is only considered as a
potential treatment of SARS, based on previous
observations in the first SARS-CoV epidemic in 2003
[4]. DRV is the most recent protease inhibitor, sharing the
same mechanism of action with LPV, but is better
tolerated and more efficacious for HIV treatment [5]. In
the only randomized trial comparing LPV/r with placebo
for the treatment of SARS-CoV-2, no benefit was
observed in the protease inhibitor arm [6]. Based on these
results, do we really have reasons to support the use of
protease inhibitors in PLWHIV with COVID-19? Are we
forgetting the successes achieved in PLWHIV in recent
years overcoming protease inhibitors use? Can we
abandon therapies based on modern, better tolerated
single-tablet regimens (STR) and go back 15 years to the
LPV/r era?
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